27
Nov

Breakthrough gene therapy technology shows success in the treatment of glaucoma, a leading cause of irreversible blindness

Selkirk, Scotland, 27 November 2018 – A major new study, published in Molecular Therapy in December 2018, has demonstrated that NanoGenics’ LipTide-ECP105 significantly improves the outcomes of glaucoma surgery. Glaucoma is the leading cause of irreversible blindness, affecting over 60 million people worldwide. Glaucoma surgery fails up to 50% of the time; LipTide-ECP105 will provide a much-needed,…
27
Nov

Partnering in Copenhagen

Well this is the first, and hopefully not the last, in a series of blogs highlighting some of the exciting developments at NanoGenics. Last week I had the pleasure of attending BioEurope along with our Director of Business development, Jonathan Lane, and 4002 other delegates. Whilst incredibly hard work (honestly no time for sightseeing) these partnering conferences…
15
Nov

Ryboquin acquires Nanogenic Solutions to advance gene therapy

The Scottish Biotech company Ryboquin, announces the acquisition of Nanogenic Solutions, to form a new product and platform company, Nanogenics Limited. The combined company, Nanogenics, is set to revolutionise gene therapy by pioneering the safe, efficacious and regular dosing of all forms of gene therapy. The inability to deliver gene therapy into target cells efficiently and with…